# HD Melphalan and SCT in Patients With IGDD or LCDD

> **NCT00681044** · PHASE2 · TERMINATED · sponsor: **Boston Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** melphalan
- **PROCEDURE:** Stem Cell Infusion

## Key facts

- **NCT ID:** NCT00681044
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681044, "HD Melphalan and SCT in Patients With IGDD or LCDD". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00681044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*